Latest Articles about BMRN

Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News

Jake L'Ecuyer — Mon, 03 Jun 2013 20:27:44 Z

Midway through trading Monday, the Dow traded up 0.38 percent to 15,172.55, while the NASDAQ fell 0.85 percent to 3,426.44. The S&P was also down, dropping 0.19 percent to 1,627.58.

Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings

Jake L'Ecuyer — Mon, 03 Jun 2013 18:34:55 Z

Following the market opening Monday, the Dow traded up 0.69 percent to 15,220.16, while the NASDAQ rose 0.12 percent to 3,460.18. The S&P was also up, gaining 0.38 percent to 1,636.87.

BioMarin Widens Loss, Maintains View - Analyst Blog

Zacks Equity Research — Mon, 29 Apr 2013 19:50:23 Z

BioMarin Pharmaceutical Inc. 's ( BMRN ) first quarter 2013 loss of 31 cents per share was wider than the Zacks Consensus Estimate of a loss of 28 cents per share and the year-ago loss of

BioMarin Attains 52-Week High - Analyst Blog

Zacks Equity Research — Fri, 12 Apr 2013 02:07:27 Z

Shares of BioMarin Pharmaceutical Inc. ( BMRN ) ended the trading session on Apr 10, 2013 by reaching its 52-week high of $64.27. The company is expected to report its first quarter 2013

BioMarin Files CTA for BMN-190 - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 18:22:52 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for BMN-190.

BMRN Seeks US Approval of Vimizim - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 00:17:57 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa). BioMarin

Data on BioMarin's BMN-701 - Analyst Blog

Zacks Equity Research — Fri, 22 Mar 2013 02:26:38 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently announced positive results on BMN-701 from the phase I/II study, POM-001. BMN-701 is a fusion protein of insulin-like growth factor 2 and acid

Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy

David Moenning — Thu, 14 Mar 2013 20:52:35 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Thursday, March 14, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

BioMarin Reports Wider Loss - Analyst Blog

Zacks Equity Research — Fri, 22 Feb 2013 22:20:01 Z

BioMarin Pharmaceutical Inc. 's ( BMRN ) fourth quarter 2012 loss of 43 cents per share was wider than the Zacks Consensus Estimate of a loss of 27 cents per share and the year-ago loss of

After-Hours Earnings Report for February 21, 2013 : AIG, HPQ, PSA, NEM, INTU, SWN, COG, JWN, SBAC, MHK, BMRN, TS

NASDAQ.com News — Fri, 22 Feb 2013 00:00:04 Z

The following companies are expected to report earnings after hours on 02/21/2013. Visit our Earnings Calendar for a full list of expected earnings releases. American International Group,

Positive Data from BMRN's PKU-016 - Analyst Blog

Zacks Equity Research — Thu, 21 Feb 2013 02:50:01 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently announced positive results from the PKU-016 ASCEND study. This is the largest randomized controlled study evaluating the safety and

BioMarin Takes Over Zacharon - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 00:57:01 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently acquired privately held biotechnology company, Zacharon Pharmaceuticals, which develops small molecules targeting pathways of glycan and

BioMarin strategy looks for further gains

David Russell — Tue, 11 Dec 2012 22:19:23 Z

BioMarin Pharmaceutical has made a giant move, and one big investor apparently thinks that it will continue to rally. optionMONSTER's Heat Seeker tracking system detected the sale of 2,500

Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

gurugk — Mon, 19 Nov 2012 22:34:31 Z

According to GuruFocus Insider Data , these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Apple Inc. ( AAPL ):

Good News for BioMarin - Analyst Blog

Zacks Equity Research — Wed, 07 Nov 2012 02:55:01 Z

BioMarin Pharmaceutical Inc. ( BMRN ) recently reported positive results from the much awaited phase III study (MOR-004) of GALNS (2mg/kg) for the treatment of patients suffering from